Fibrocell Science Announces Delay in Filing Quarterly Report on Form 10Q
[Business Wire] – Fibrocell Science, Inc. , an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that has file moreView todays social media effects on FCSCView the latest stocks trending across Twitter. Click to view dashboardSee who Fibrocell is hiring next, click […]
